How Much Does Leukemia Treatment Cost? Price by Procedure and Country

Where you treat leukemia can change the bill more than what you treat it with. A bone marrow transplant runs $400,000 – $800,000 in the US and $36,000 – $56,400 in Turkey. The protocol is the same.

Chemotherapy shows the same pattern: a full course costs $20,000 – $50,000 in the US and $8,000 – $16,000 in Turkey.

All five methods are available at partner clinics abroad: chemotherapy, targeted drugs, radiation therapy, CAR T-cell therapy and a bone marrow transplant. The five destinations with a current price for every method are Turkey, Thailand, Spain, Israel and Germany.

This article gives the price of each treatment method in those five countries, next to the US baseline. It also shows what drives the bill up and what a treatment package covers. And it compares the cost across the four main types: acute lymphoblastic (ALL), acute myeloid (AML), chronic lymphocytic (CLL) and chronic myeloid (CML) leukemia.

Key takeaways on leukemia treatment cost

• Savings: about 50 – 90% less than US prices in all five destinations.
• Chemotherapy: $8,000 – $16,000 for a full course in Turkey, against $20,000 – $50,000 in the US.
• Bone marrow transplant: $36,000 – $56,400 in Turkey, against $400,000 – $800,000 in the US.
• CAR T-cell therapy is the priciest option. Israel has the lowest band at $84,000 – $89,400, against $450,000 – $600,000 in the US.
• Targeted drugs run $1,000 – $50,000 a year abroad and $25,000 – $55,000 a year in the US.

Table of contents

1. Average leukemia treatment cost by procedure
2. Leukemia treatment cost by type: ALL, AML, CLL, CML
3. What leukemia treatment cost depends on
4. 5 best countries for leukemia treatment
5. What the leukemia treatment package includes
6. Insurance coverage for leukemia treatment
7. Why choose Bookimed
8. FAQ

Average leukemia treatment cost by procedure

Leukemia is expensive to treat, especially in the US. A University of Texas Southwestern analysis modelled the lifetime cost of chronic lymphocytic leukemia (CLL) care in the US. It came to about $1.14 million per patient, spread over roughly 8 years of care.

Every new line of therapy cost more than the one before. First-line treatment averaged about $140,000 a year, and by the fifth line the figure reached about $235,000 a year.

Drugs are what drive that total. Drug acquisition and administration accounted for 77% of the lifetime cost, and emergency and inpatient care for another 20%. Hospital stays and the patient's age at diagnosis moved the number next.

At accredited hospitals in Turkey, Thailand, Israel, Spain and Germany, the same procedures cost 50 – 90% less. All ranges below are in USD.

Leukemia is treated with a mix of the following options:

• anticancer drug therapy (chemotherapy, biologic agents);
• immunotherapy;
• bone marrow or stem cell transplantation;
• radiation therapy;
• CAR T-cell therapy;
• targeted therapy.

Chemotherapy for leukemia

Chemotherapy is the backbone of leukemia treatment and one of the widest US-vs-abroad price gaps. A full US course typically runs $20,000 – $50,000. In Turkey the same course costs $8,000 – $16,000, and Israel sits closest to US pricing at $28,500 – $62,000.

The individual drug moves the bill as much as the country does. In Turkey, Venclexta runs about $2,500 – $3,500 a month. It is prescribed for CLL, lymphocytic lymphoma and acute myeloid leukemia. Idhifa, used for AML, runs about $10,000 – $12,000 a month there, or $70,000 – $120,000 for a full year. A month of Idhifa in the US costs around $36,000.

Bone marrow transplantation

Bone marrow (or stem cell) transplantation is the single largest cost in leukemia care. The price packages a long hospital stay, cell processing, a donor search, conditioning chemotherapy and months of follow-up. Here is what it costs country by country:

The type of transplant matters as much as the country. An autologous transplant uses the patient's own stem cells and costs the least. An allogeneic transplant needs a donor, and the price climbs as the match gets harder to find. Current transplant packages at Turkish partner clinics show the spread:

Targeted drug therapy

Targeted drugs act on specific molecular changes inside leukemia cells. The main groups are tyrosine kinase inhibitors for CML, BCL-2 inhibitors for CLL, and FLT3 and IDH1/2 inhibitors for AML. Reported response rates sit at around 70 – 80%, depending on the drug and the patient's molecular profile.

Because they spare more healthy cells than conventional chemotherapy, patients usually find them easier to live with. The practical benefits are:

• most of these drugs are taken orally at home, so hospital time drops sharply;
• blood cell counts fall less, which lowers the risk of infection;
• treatment continues steadily for years instead of in short intensive bursts.

Side effects still occur. The most common ones affect the skin, nails and digestion. That is why a hematologist matches the drug to the molecular profile. Here is the annual medication bill by country:

Radiation therapy

Radiation therapy is not the main treatment for leukemia. It is used to prepare a patient for a transplant. It also targets disease concentrated in the bone marrow, spleen or central nervous system. The number of sessions depends on the case, so clinics quote a price per session:

Chimeric antigen receptor T-cell therapy (CAR T-cell therapy)

CAR T-cell therapy is the newest option and the most complex to deliver. The patient's own T-cells are collected, re-engineered in a laboratory to recognize the leukemia, multiplied and infused back. The price covers that personalized manufacturing, a specialist team and an extended hospital stay for monitoring.

It is used mainly for B-cell ALL and for aggressive lymphomas that returned after chemotherapy. The trial behind the first approved CAR T-cell product enrolled children and young adults with relapsed B-cell ALL. 81% reached remission within three months of one infusion.

Israel carries the lowest band of the five destinations. Sheba Medical Center prices its CAR T-cell programs for blood cancers at $84,000 – $89,400. That includes the pediatric protocols for ALL and AML. Country bands look like this:

Outpatient drug treatment

Monthly outpatient drug treatment is often the longest-running line item. It covers agents such as venetoclax, ibrutinib, azacitidine and gilteritinib. Monthly bands look like this:

• Turkey: $600 – $1,000;
• Thailand: $950 – $2,000;
• Germany: $1,000 – $2,500;
• Spain: $1,200 – $2,500;
• Israel: $16,500 – $32,500;
• US baseline: $3,000 – $6,000.

Acute leukemia is the most cost-intensive blood cancer to treat. In Medicare claims data, the month of diagnosis alone averaged $35,202 for acute leukemia against $11,568 for chronic leukemia. Two-year out-of-pocket spending reached $21,852 for acute leukemia in fee-for-service Medicare.

For pediatric acute lymphoblastic leukemia, an ASH/Blood study put the three-year US cost of care at around $537,000. Roughly 58% of that fell in the first eight months of therapy, when admissions and drug intensity peak.

Leukemia treatment cost by type: ALL, AML, CLL, CML

The four main subtypes drive very different bills. What separates them is how urgent, how intensive and how long each course of care is. Acute leukemias front-load the spend, while chronic leukemias spread it over years of maintenance drugs.

Acute lymphoblastic leukemia (ALL)

ALL moves fast and needs immediate multi-drug induction chemotherapy. That is followed by consolidation and up to two years of maintenance therapy. It is the most common childhood leukemia, and the pediatric course is the best documented one.

An ASH/Blood analysis estimated roughly three years of pediatric ALL therapy at about $537,000 in the US. Adult ALL follows a similar high-intensity template, set out in the NCI adult ALL treatment overview.

Acute myeloid leukemia (AML)

AML is treated even more intensively in the short term. Induction chemotherapy usually requires a 4 – 6 week hospital admission, followed by consolidation cycles. Higher-risk patients then go on to an allogeneic stem cell transplant.

That transplant is the single biggest driver of total AML cost. It runs $36,000 – $56,400 in Turkey and $400,000 – $800,000 in the US. FLT3 and IDH1/2 targeted drugs add ongoing monthly cost after remission.

Chronic lymphocytic leukemia (CLL)

CLL is a marathon rather than a sprint. Patients are often watched for years before treatment starts. When it does start, it usually means long-running targeted or immunotherapy protocols rather than a transplant.

Those drugs stack up over time. The University of Texas Southwestern study put lifetime CLL care in the US at about $1.14 million. The total rises with every new line of therapy.

Older patients show the same pattern. In fee-for-service Medicare, two-year out-of-pocket spending averaged $11,224 for chronic leukemia.

Chronic myeloid leukemia (CML)

CML has been transformed by tyrosine kinase inhibitors – imatinib, dasatinib, nilotinib, bosutinib and ponatinib. Most patients now live for years on oral therapy without a transplant. That shifts the cost picture toward a very long monthly drug bill.

Targeted therapy runs $1,000 – $50,000 a year across the five destinations. In the US it is $25,000 – $55,000 a year. Over a decade on treatment, that yearly gap compounds into a six-figure difference.

Why the acute vs chronic split matters for cost

Acute leukemias (ALL, AML) front-load spend on induction, long hospital stays and, often, a transplant. Chronic leukemias (CLL, CML) spread the cost over years of maintenance drugs. The destination matters most when the therapy runs long, because a small monthly difference becomes a large annual one.

What leukemia treatment cost depends on

Leukemia treatment cost is not one number. It is the sum of a series of decisions, some clinical and some logistical. The main levers:

• Leukemia subtype and stage. Acute leukemias (ALL, AML) need intensive induction and often a transplant. That front-loaded cost sits far above chronic subtypes (CLL, CML), managed with long-running oral therapy.
• Treatment protocol intensity and duration. A short single-line targeted regimen costs a fraction of a multi-cycle chemotherapy course. Extending a course to a second or third line multiplies the drug and admission bill.
• Bone marrow transplant donor type. Autologous transplants use the patient's own cells and cost the least. Matched-sibling allogeneic transplants cost more. Unrelated-donor and haploidentical transplants cost the most, because of the donor search, HLA matching and cell processing.
• Length of hospitalization and supportive care. Isolation rooms during neutropenia, antibiotics, antifungals, transfusions and growth factors accumulate quickly. A 4 – 6 week transplant admission can add tens of thousands even at partner clinics abroad.
• Country and clinic tier. The same protocol costs far less at a JCI-accredited clinic in Turkey or Thailand. The gap against a top US academic center reaches 50 – 90%, mostly from salary, real-estate and drug pricing.
• Patient's overall health, age and comorbidities. Older or frailer patients need more supportive care and longer hospital stays. That raises both the medical bill and the accommodation bill.
• Whether the disease has spread (for example, CNS involvement in ALL). Extra imaging, intrathecal chemotherapy or CNS radiation adds to the base protocol.
• Doctor and hospital reputation. Top-ranked hematology teams charge more. The tradeoff is faster access to newer drugs and higher-volume transplant units.

5 best countries for leukemia treatment

Five countries stand out for leukemia care: Turkey, Israel, Spain, Germany and Thailand. Partner clinics there run accredited hematology and transplant programs, and each procedure has a current price. The same treatment costs about 50 – 90% less than in the US, depending on the country and the method.

Outcomes are what make that gap worth acting on. Five-year relative survival for leukemia in US national data is 68.6%. Clinics in all five countries treat to the same international protocols.

Turkey

Turkey is the most affordable of the five for every leukemia procedure. Typical bands for Turkish clinics:

• Chemotherapy full course: $8,000 – $16,000 (about 68% less than the US $20,000 – $50,000 baseline).
• Targeted therapy: $1,000 – $4,600 per year (about 90% less than US).
• Bone marrow transplant: $36,000 – $56,400 (about 90% less than the US $400,000 – $800,000 baseline).
• CAR T-cell therapy: $150,000 – $225,000 (about 65% less than US).
• Radiation therapy per session: $4,000 – $7,000 (about 78% less than US).

A transplant package at a Turkish partner clinic usually covers:

• the transplant itself and the ward stay, about 30 days;
• the pre-transplant workup, including bone marrow biopsy and cytogenetic analysis;
• consultations with the treating hematologist;
• a follow-up examination after discharge;
• airport – clinic – airport transfer and language assistance.

Hotel accommodation for the recovery period, usually about 80 days, is paid separately.

Two Turkish clinics stand out. Medipol Mega University Hospital is a JCI-accredited complex whose oncology and transplant programs cover hematology oncology. Istanbul Florence Nightingale Hospital holds JCI and ISO accreditation.

Israel

Israel is a strong choice for complex cases, especially CAR T-cell therapy. It carries the lowest band of the five. Bands for Israel:

• Chemotherapy full course: $28,500 – $62,000.
• Targeted therapy: $9,500 – $19,500 per year (about 65% less than US).
• Bone marrow transplant: $79,000 – $167,000 (about 75% less than US).
• CAR T-cell therapy: $84,000 – $89,400 (about 82% less than US, the lowest band of the five).
• Radiation therapy per session: $12,500 – $23,500.

Sheba Medical Center runs the widest CAR T-cell lineup. It has separate programs for ALL, AML, CLL, multiple myeloma and non-Hodgkin lymphomas. A coordinator can match a clinic to the diagnosis and confirm what its program covers.

Spain

Spain pairs European standards with among the lowest bone-marrow-transplant prices in Western Europe. Bands for Spain:

• Chemotherapy full course: $20,000 – $40,000.
• Targeted therapy: $15,000 – $25,000 per year.
• Bone marrow transplant: $71,800 – $189,200 (about 75% less than US at the low end).
• CAR T-cell therapy: $330,000 – $420,000.
• Radiation therapy per session: $5,000 – $9,000.

Centro Médico Teknon is a JCI-accredited Barcelona center with its own oncology institute. Sant Joan de Déu Barcelona Children's Hospital is a leading European pediatric center with dedicated childhood-leukemia and bone-marrow-transplant programs.

Germany

Germany is the highest-priced of the five and the closest to US quality-of-care standards. Its research hospitals invest heavily in cell therapies. Bands for Germany:

• Chemotherapy full course: $25,000 – $45,000.
• Targeted therapy: $20,000 – $50,000 per year.
• Bone marrow transplant: $180,000 – $270,000 (about 55% less than US).
• CAR T-cell therapy: $350,000 – $500,000.
• Radiation therapy per session: $8,000 – $16,000.

A featured clinic is Nordwest Clinic. Its Oncology and Hematology Center is ESMO-certified, one of only 22 centers worldwide with that status.

Thailand

Thailand is Asia's most established medical-tourism hub for blood cancer. It offers international accreditation, no waiting lists and a full modality lineup. Bands for Thailand:

• Chemotherapy full course: $15,000 – $22,000.
• Targeted therapy: $7,000 – $13,000 per year.
• Bone marrow transplant: $50,000 – $80,000 (about 87% less than US).
• CAR T-cell therapy: $250,000 – $350,000.
• Radiation therapy per session: $5,500 – $10,000.

Thai partner centers cover chemotherapy, radiation therapy, stem cell transplantation, targeted therapy and immunotherapy, plus supportive care such as transfusions. A coordinator can shortlist a hospital and confirm which modalities it offers for the case.

What the leukemia treatment package includes

Services in a leukemia treatment package vary by country, hospital, diagnosis, current health state and treatment plan. Below is an overview of what is typically included and excluded.

Additional services may include psychological support, nutrition counseling and emergency management. Patients also get 24/7 assistance – Bookimed medical coordinators are available for any queries and emergencies.

Across partner clinics in Germany, Spain, Israel, Thailand and Turkey, the following are usually not covered:

• Travel expenses.

• Accommodation. Some clinics don't arrange hotel stays, so these expenses are the patient's responsibility.

• Medications outside the clinic. Medicine prescribed outside the hospital, such as oral chemotherapy drugs, is excluded.

• Complication management. If a complication or side effect arises after the primary therapy, extra hospital stays or procedures are charged separately.

• Interpreter services. Language assistance may be available but often comes at an extra charge.

• Insurance and administrative issues. Costs for medical insurance processing or other administrative services aren't covered.

Risks and safety to plan for

Leukemia treatment keeps getting safer, and the survival curve shows it. In a 35-year cohort study of allogeneic transplants, three-year survival rose from 41% in the 1990s to 58% today. Progression-free survival rose from 37% to 49% over the same period.

Patients also got older across those decades, with the median age moving from 41 to 54. Outcomes improved anyway, because supportive care now prevents or catches complications early.

The main risk during intensive chemotherapy or a transplant is still infection while the immune system recovers. Accredited centers keep it low with isolation nursing, preventive antibiotics and growth-factor support. Ask each clinic how it handles complication management and follow-up. That care, and its cost, varies by package.

Insurance coverage for leukemia treatment

Insurance coverage for leukemia treatment varies by country, insurer and plan tier. It is worth checking the specific plan before committing to a treatment path. As a general rule:

• Standard health insurance in the US, UK and EU typically covers chemotherapy, radiation therapy and allogeneic bone marrow transplant. Cover applies at an in-network hospital, subject to deductibles, coinsurance and out-of-pocket maximums.
• Newer cell-based therapies (CAR T-cell) are covered by some payers under tight pre-authorization criteria. Out-of-pocket exposure can still be substantial, so confirm with the insurer before scheduling.
• Outpatient targeted drugs (oral therapies for CLL, CML) usually run through the pharmacy benefit. Formulary tier, prior authorization and patient-assistance programs make a large difference to the final bill.

For treatment abroad, budget for insurance separately:

• Most standard travel policies exclude planned medical treatment. They cover unexpected emergencies, not the elective procedure the trip is booked for. A short-term medical-travel or complication policy that names the planned procedure is the right cover.
• Home-country insurance rarely reimburses treatment abroad in full. Some EU public systems partially reimburse cross-border care at accredited providers, decided case by case.
• Ask the Bookimed coordinator for a written cost breakdown before signing. It should list clearly what the clinic's package includes and excludes. That document is what an insurer or complication-insurance provider will ask for.

Why choose Bookimed

Bookimed is a medical-travel platform that helps international patients compare and book care at partner clinics worldwide. For leukemia, that means one place to compare cost, protocol, transplant capability and accreditation. The five destinations are Turkey, Israel, Spain, Germany and Thailand.

• Verified authorization. Bookimed checks that a clinic holds the right national authorization before listing it. Every hospital in the leukemia lineup carries the standard hematology and transplant credentials.
• Free coordinator support. A Bookimed medical coordinator handles the initial consultation request, price comparison and clinic communication at no cost to the patient. The price shown is the clinic's price.
• Side-by-side price comparison. Each clinic profile lists what the package includes and excludes, plus current offers and typical duration. That makes the total bill comparable, not just the headline price.
• Real patient reviews. Each clinic page carries verified reviews from Bookimed patients who completed treatment there. They cover outcomes and coordinator experience for the specific procedure.
• 24/7 patient support. Coordinators stay in touch through the whole trip, from the first quote to the follow-up appointment. They can escalate to the clinic's international patient office if anything changes.

FAQ

What is the cost of chemotherapy for leukemia?

A full course of leukemia chemotherapy runs about $20,000 – $50,000 in the US. At partner clinics abroad the same course costs less:

• Turkey: $8,000 – $16,000;
• Thailand: $15,000 – $22,000;
• Spain: $20,000 – $40,000;
• Germany: $25,000 – $45,000;
• Israel: $28,500 – $62,000.

Turkey is the most affordable and Israel sits closest to US pricing. A single session costs $2,400 – $3,800 in Turkey against $8,000 – $18,000 in the US.

The final bill depends on which drugs the protocol uses and how many cycles are needed. It also depends on whether inpatient supportive care – isolation nursing, transfusions and anti-infectives – is bundled into the package.

How much is blood cancer treatment?

"Blood cancer" covers leukemia, lymphoma and multiple myeloma, so the cost swings widely with the subtype and the plan. Using leukemia as the anchor:

• chemotherapy course: $20,000 – $50,000 in the US, $8,000 – $45,000 abroad;
• bone marrow transplant: $400,000 – $800,000 in the US, $36,000 – $270,000 abroad;
• CAR T-cell therapy: $450,000 – $600,000 in the US, $84,000 – $500,000 abroad.

Lymphoma and multiple myeloma follow the same pattern for the methods they share with leukemia. Savings at partner clinics abroad reach about 50 – 90%.

In practice the destination affects the final bill more than the specific blood-cancer subtype does. That makes it worth comparing accredited clinics in several countries first.

How much does acute lymphoblastic leukemia treatment cost in the USA?

Pediatric ALL is the best documented case. An ASH/Blood study put the three-year US cost of care at about $537,000. Roughly 58% of that spend fell in the first eight months, when admissions and drug intensity peak.

Adult ALL combines intensive induction chemotherapy, further consolidation cycles and up to two years of maintenance. That typically pushes the total into the low-to-mid six figures at a US center. The NCI outlines the standard adult protocol.

Costs ease during the long maintenance phase. Monitoring, periodic imaging and any treatment of central-nervous-system involvement keep adding to the total. Treating the same protocol abroad can lower that part of the bill by 50 – 90%.

Why is leukemia treatment so expensive?

The drugs are the biggest driver. Modern targeted agents and CAR T-cell products are among the most expensive medicines in oncology. Each later line of therapy tends to cost more than the one before. In the US CLL analysis, drug acquisition and administration made up 77% of the lifetime total.

Long inpatient stays come next. Induction chemotherapy and transplant conditioning often mean four to six weeks in an isolation room. That comes with continuous antibiotics, antifungals, transfusions and growth-factor support.

Allogeneic transplants add a donor search, HLA matching and cell processing. CAR T-cell therapy needs bespoke manufacturing of each patient's own engineered immune cells.

Chronic leukemias are costly for a different reason. They run for years rather than months, so even a modest monthly drug price compounds into a large lifetime total. Country and clinic tier then decide how heavily each of these blocks lands.

How successful is leukemia treatment?

Five-year relative survival for leukemia overall is 68.6% in US national data, and it has been climbing for four decades. Outcomes depend heavily on the subtype and the patient's age at diagnosis.

Childhood acute lymphoblastic leukemia is among the most treatable cancers in modern oncology. Acute myeloid leukemia in adults is harder: about a third are alive five years after diagnosis, with SEER five-year relative survival around 33%.

Chronic leukemias are usually managed as long-term conditions, with patients often living for years on oral therapy. Subtype, genetics and age move the numbers a lot. The most useful estimate is the one a hematologist calculates for the specific diagnosis.

Which country is best for leukemia treatment?

On price alone, Turkey is the most affordable across every leukemia procedure. A chemotherapy course costs $8,000 – $16,000 there and a bone marrow transplant $36,000 – $56,400.

For CAR T-cell therapy, Israel carries the lowest band at $84,000 – $89,400. Sheba Medical Center runs the established cell-therapy programs behind it.

For an allogeneic transplant with EU-standard follow-up, Germany and Spain are strong choices. Thailand is Asia's most established hub for blood cancer, with international accreditation and no waiting lists. Across all five, the same procedures cost about 50 – 90% less than in the US.

The practical way to choose is to weigh three things together: the protocol, the clinic's transplant capability and its accreditations. A Bookimed coordinator can shortlist clinics against the exact case at no cost.

Which hospitals are best for leukemia treatment?

A single global "best hospital" ranking shifts every year and rarely fits an individual case. Bookimed instead publishes a shortlist of leading hematology and transplant centers per country. Each carries verified accreditations and real patient reviews.

Featured leukemia clinics include:

• Turkey: Medipol Mega University Hospital, Istanbul Florence Nightingale Hospital;
• Spain: Centro Médico Teknon, Sant Joan de Déu Barcelona Children's Hospital;
• Germany: Nordwest Clinic;
• Israel: Sheba Medical Center, which runs the widest CAR T-cell lineup.

The right choice depends on the modality needed. That could be an active CAR T-cell program for relapsed disease, or a high-volume allogeneic transplant unit. Matching a clinic's strengths to the diagnosis with a coordinator is the fastest way to narrow it down.